Hospital chains weigh drug price cap impact as Supreme Court scrutiny looms | Industry News


India’s leading hospital chains are divided over the potential impact of the government’s cap on trade margins for oncology and other drugs, which came into effect in early November, with some expecting pressure on profitability while others see limited exposure.

 

The issue featured prominently in the companies’ Q2FY27 earnings calls, alongside questions on a Supreme Court case concerning the commercialisation of private healthcare and the broader implications for hospital pricing and profitability.

 

Fortis flags pressure on margins

 

Fortis Healthcare has indicated that the new pricing norms could weigh on profitability, although it is yet to quantify the impact.

 

The company’s Chief Financial Officer, Vivek Goyal, said during its Q2 earnings call that the circular was recent and the company was still assessing its implications. Drugs account for around a third of Fortis’ oncology revenue, though the price restrictions do not cover all drugs and treatment packages.

  

The hospital chain expects its margins to remain around 22 per cent in the current financial year, after accounting for employee stock ownership plan (ESOP) costs. However, it has refrained from providing margin guidance for the next financial year, citing uncertainty around drug pricing.

 

Others assess exposure

 

Apollo Hospitals’ pharmacy arm said it is waiting for revised maximum retail prices before assessing the effect and expects “some impact”.

 

Max Healthcare said it is still working out its exposure, adding that chemotherapy accounts for roughly 30 per cent of its oncology revenue and that part of its drug business is unaffected. Max also pointed out that the earlier revision of CGHS rates, which led it to drop some high-value chemotherapy drugs for institutional patients, is already reflected in its numbers. Jupiter Life Line Hospitals said it has not modelled the effect because it cannot influence the margin and promised a ballpark figure after the current quarter.

 

Max Healthcare is also assessing its exposure. The company said chemotherapy contributes around 30 per cent of its oncology revenue, while a portion of its drug business remains outside the scope of the restrictions. It added that the impact of an earlier revision in Central Government Health Scheme (CGHS) rates, which prompted it to discontinue certain high-value chemotherapy drugs for institutional patients, has already been factored into its financial performance.

 

Jupiter Life Line Hospitals said it has not yet incorporated the potential impact into its estimates, as the company has limited control over the margins. It expects to provide a broad estimate after the current quarter.

 

Manipal, Aster see limited impact

 

In contrast, Manipal Hospitals and Aster DM Healthcare expressed relatively little concern over the new regulations.

 

Manipal Hospitals Chief Executive Officer Dilip Jose said during the company’s Q2 earnings call that oncology contributes around 12 per cent of the network’s revenue, with chemotherapy accounting for only a portion of this. The share of drugs covered under the price restrictions is smaller still, limiting the potential impact on the overall business.

 

Aster DM Healthcare Managing Director Varun Khanna said during the company’s Q2 earnings call that it does not view its business primarily through the pharmacy segment and has welcomed measures aimed at making cancer treatment more affordable.

 

With nearly 75 per cent of its operations in smaller cities, where access to cancer care remains limited, lower treatment costs could also support patient volumes, he said.

 

Hospitals seek shift to service-based pricing

 

The discussions also brought the debate over the pricing of private healthcare into focus, with hospital executives arguing that the industry’s business model is centred on delivering integrated medical services rather than selling individual drugs.

 

Apollo Hospitals Managing Director Suneeta Reddy said during the company’s Q2 earnings call that drug pricing has often been used as a proxy for the services provided by hospitals, adding that the industry hopes to move towards a service-based pricing framework.

 

Max Healthcare Chairman Abhay Soi said during the company’s Q2 earnings call that the matter was before the Supreme Court and urged stakeholders to examine the legal pleadings rather than rely on media reports. He also highlighted that the median net profit margin for the hospital sector is around 9 per cent.

 

Khanna said Aster’s net profit margin was around 10 per cent and cautioned that further investments in healthcare infrastructure would depend on the sector generating adequate returns.

 

India would need approximately 1.5 million additional hospital beds over the next decade, requiring investments of around $130 billion, he estimated.

 

Jupiter Life Line Hospitals Chief Executive Officer Ankit Thakker declined to comment on the court proceedings, saying the company would abide by the law.

 

Kerala adds to regulatory concerns

 

Aster also faced questions on the Kerala Assembly committee’s recommendation to extend price controls across a wider range of hospital services.

 

Khanna said it was difficult to anticipate the outcome of the recommendation, describing Kerala as one of the country’s strongest healthcare systems. The company would engage constructively with the state government on the matter, he said.

 

Latest Posts

Don't Miss

Amit Shah’s talks offer rejected as Arunachal anti-dam forum demands troop withdrawal ahead of talks

The Siang Indigenous Farmers’ Forum (SIFF), one of the prominent

China Reviews Impact of U.S. Supreme Court Ruling on Trump-Era Tariffs Ahead of High-Level Talks

Beijing: China on Monday said it is conducting a comprehensive

Bastar Olympic 2025: Chief Minister Vishnudev Sai Inaugurates Divisional-Level Event, Calls Bastar a Rising Symbol of Peace and Prosperity

Raipur Chhattisgarh Chief Minister Vishnudev Sai inaugurated the divisional-level competitions

US FDA grants tentative nod to Dr Reddy’s twice-yearly HIV prevention drug | Health News

Dr Reddy’s Laboratories has received tentative approval from the US